• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MediWound Ltd.

    10/1/24 8:23:53 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    SC 13G 1 ea0216242-13gyelin_medi.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.   )*

     

    MediWound Ltd.

    (Name of Issuer)

     

    Ordinary shares, par value NIS 0.07 per share

    (Title of Class of Securities)

     

    M68830112

    (CUSIP Number)

     

    September 26, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. M68830112 13G Page 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Dov Yelin

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

      

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    ---

    6

    SHARED VOTING POWER

     

    750,743 (*)

    7

    SOLE DISPOSITIVE POWER

     

    ---

    8

    SHARED DISPOSITIVE POWER

     

    750,743 (*)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    750,743 (*)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.96% (*) (**)

    12

    TYPE OF REPORTING PERSON (See instructions)

     

    IN

     

    (*)The beneficial ownership of the securities reported herein is described in Item 4(a).

     

    (**)Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP).

     

     

     

    CUSIP No. M68830112 13G Page 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Yair Lapidot

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

      

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    ---

    6

    SHARED VOTING POWER

     

    750,743 (*)

    7

    SOLE DISPOSITIVE POWER

     

    ---

    8

    SHARED DISPOSITIVE POWER

     

    750,743 (*)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    750,743 (*)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.96% (*) (**)

    12

    TYPE OF REPORTING PERSON (See instructions)

     

    IN

     

    (*)The beneficial ownership of the securities reported herein is described in Item 4(a).

     

    (**)Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP).

     

     

     

    CUSIP No. M68830112 13G Page 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Yelin Lapidot Holdings Management Ltd.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

      

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Israel

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    ---

    6

    SHARED VOTING POWER

     

    750,743 (*)

    7

    SOLE DISPOSITIVE POWER

     

    ---

    8

    SHARED DISPOSITIVE POWER

     

    750,743 (*)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    750,743 (*)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.96% (*) (**)

    12

    TYPE OF REPORTING PERSON (See instructions)

     

    CO

     

    (*)The beneficial ownership of the securities reported herein is described in Item 4(a).

     

    (**)Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP)

     

     

     

    Item 1. (a)Name of Issuer:

     

    MediWound Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    42 Hayarkon Street, Yavne 8122745, Israel

     

    Item 2. (a)Name of Person Filing:

     

    Dov Yelin

     

    Yair Lapidot

     

    Yelin Lapidot Holdings Management Ltd.

     

    (b)Address of Principal Business Office:

     

    Dov Yelin – 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel

     

    Yair Lapidot – 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel

     

    Yelin Lapidot Holdings Management Ltd. – 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel

     

    (c)Citizenship or Place of Incorporation:

     

    Dov Yelin – Israel

     

    Yair Lapidot – Israel

     

    Yelin Lapidot Holdings Management Ltd. – Israel

     

    (d)Title of Class of Securities:

     

    Ordinary shares, par value NIS 0.07 per share

     

    (e)CUSIP Number:

     

    M68830112

     

    Item 3.Not applicable.

     

    5

     

     

    Item 4.Ownership:

     

    (a)Amount beneficially owned:

     

    See row 9 of cover page of each reporting person.

     

    On September 26, 2024, the securities reported herein were beneficially owned as follows:

     

    ●522,645 Ordinary Shares (representing 4.84% of the total Ordinary Shares outstanding) beneficially owned by provident funds managed by Yelin Lapidot Provident Funds Management Ltd.

     

    ●228,098 Ordinary Shares (representing 2.11% of the total Ordinary Shares outstanding) beneficially owned by mutual funds managed by Yelin Lapidot Mutual Funds Management Ltd.

     

    The securities reported herein are beneficially owned by provident funds managed by Yelin Lapidot Provident Funds Management Ltd. and/or mutual funds managed by Yelin Lapidot Mutual Funds Management Ltd. (the “Subsidiaries”), each a wholly-owned subsidiary of Yelin Lapidot Holdings Management Ltd. (“Yelin Lapidot Holdings”). Mr. Yelin owns 24.38% of the share capital and 25.00% of the voting rights of Yelin Lapidot Holdings, Mr. Lapidot owns 24.62% of the share capital and 25.00% of the voting rights of Yelin Lapidot Holdings. Messrs Yelin and Lapidot are responsible for the day-to-day management of Yelin Lapidot Holdings. In accordance with the Shareholders’ Agreement, dated December 5, 2018, until the End of the “Suspension Period” Messrs Yelin and Lapidot are entitled to jointly appoint the majority of the members of Yelin Lapidot Holdings board. The Subsidiaries operate under independent management and make their own independent voting and investment decisions. Any economic interest or beneficial ownership in any of the securities covered by this report is held for the benefit of the members of the provident funds or mutual funds, as the case may be. This Statement shall not be construed as an admission by Messrs. Yelin and Lapidot, Yelin Lapidot Holdings or the Subsidiaries that he or it is the beneficial owner of any of the securities covered by this Statement, and each of Messrs. Yelin and Lapidot, Yelin Lapidot Holdings, and the Subsidiaries disclaims beneficial ownership of any such securities.

     

    (b)Percent of class:

     

    See row 11 of cover page of each reporting person

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See row 5 of cover page of each reporting person

     

    6

     

     

    (ii)Shared power to vote or to direct the vote:

     

    See row 6 of cover page of each reporting person and note in Item 4(a) above

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See row 7 of cover page of each reporting person

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See row 8 of cover page of each reporting person and note in Item 4(a) above

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another:

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    October 1, 2024

     

      Dov Yelin
       
      /s/ Dov Yelin
      By: Dov Yelin
       
      Yair Lapidot
       
      /s/ Yair Lapidot
      By: Yair Lapidot
       
      Yelin Lapidot Holdings Management Ltd.
       
      /s/ Dov Yelin
      By: Dov Yelin
      Title: Joint Chief Executive Officer

     

    8

     

     

    EXHIBIT NO.   DESCRIPTION
         
    Exhibit 1   Joint Filing Agreement filed by and among the Reporting Persons, dated as of October 1, 2024.

     

     

    9

     

     

    Get the next $MDWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

      VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

      5/21/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

      YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers. The article, titled "Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of

      5/13/25 7:30:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      11/14/24 7:55:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      10/23/24 2:57:43 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by MediWound Ltd.

      SC 13G - MediWound Ltd. (0001593984) (Subject)

      10/1/24 8:23:53 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Financials

    Live finance-specific insights

    See more

    $MDWD
    SEC Filings

    See more

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

      VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

      5/21/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica

      3/19/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/21/25 7:07:42 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      5/15/25 4:35:05 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      4/7/25 4:04:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

      8/16/24 4:36:54 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/30/22 4:38:06 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/29/22 1:11:07 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Alliance Global Partners initiated coverage on MediWound with a new price target

      Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

      5/2/25 8:15:09 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on MediWound with a new price target

      Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

      2/28/25 7:39:12 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Maxim Group reiterated coverage on MediWound with a new price target

      Maxim Group reiterated coverage of MediWound with a rating of Buy and set a new price target of $30.00 from $25.00 previously

      7/16/24 8:08:28 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Leadership Updates

    Live Leadership Updates

    See more
    • MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

      YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

      11/21/23 7:00:00 AM ET
      $ENLV
      $MDWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

      YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

      11/8/23 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

      YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi

      3/16/23 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care